Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

asthenia/bröstcancer

Länken sparas på Urklipp
Sida 1 från 549 resultat

Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND The objectives of this pilot study were to evaluate the safety and efficacy of the central nervous system stimulant methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel. METHODS Patients with early breast cancer who presented asthenia >3 on the
Sixty-four consecutive patients with advanced breast cancer were included in a study designed to determine the prevalence of asthenia and its association with other clinical features. The Asthenia Score (AS, the average of four tests designed by our group to assess asthenia) was 59 +/- 9 for

Analysis of factors related to arm weakness in patients with breast cancer-related lymphedema.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE The aim of this study was to evaluate the ratio of significant weakness in the affected arm of breast cancer-related lymphedema patients to their unaffected side. Another purpose was to identify factors related to arm weakness and physical function in patients with breast cancer-related
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We

Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Muscle weakness and cachexia are significant paraneoplastic syndromes of many advanced cancers. Osteolytic bone metastases are common in advanced breast cancer and are a major contributor to decreased survival, performance, and quality of life for patients. Pathologic fracture caused by osteolytic

Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do not revert bone destruction. In metastatic
The weakness is one of the negative factors that degrade cancer patients’ quality of life. The nature of weakness may be multifactorial but among mechanisms of development of weakness a syndrome of chronic inflammation plays a crucial role. Therapy aimed at reducing of inflammation degree allows
Several recently published studies describe moderate to severe cognitive dysfunction in breast cancer survivors who were treated with adjuvant chemotherapy 1-5 years before undergoing extensive neuropsychological testing. While these studies are hypothesis-generating and preliminary given their

Asthenia in breast cancer.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE This article is a report of a review of the effectiveness of exercise programmes on shoulder mobility and lymphoedema in postoperative patients with breast cancer having axillary lymph node dissection, as revealed by randomized controlled trials. BACKGROUND Breast cancer is the most common

Breast cancer in European Union: an update of screening programmes as of March 2014 (review).

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Breast cancer, a major cause of female morbidity and mortality, is a global health problem; 2008 data show an incidence of ~450,000 new cases and 140,000 deaths (mean incidence rate 70.7 and mortality rate 16.7, world age-standardized rate per 100,000 women) in European Union Member States.
Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. In this dose-finding study, patients were randomized to olaparib 10, 30, 100, 200 or 400 mg

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND This exploratory study examined the pharmacokinetics, safety, and antitumor activity of sunitinib plus docetaxel in patients with HER-2-negative advanced breast cancer. METHODS Patients with HER-2-negative disease who had received prior adjuvant anthracycline-based therapy received

Does architectural lighting contribute to breast cancer?

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE There is a growing interest in the role that light plays on nocturnal melatonin production and, perhaps thereby, the incidence of breast cancer in modern societies. The direct causal relationships in this logical chain have not, however, been fully established and the weakest link is an

Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A phase II study of carboplatin and etoposide as salvage polychemotherapy in metastatic, infiltrating breast carcinoma was carried out with 25 multiply pretreated patients. Six of 25 patients (24%) had a partial response that lasted an average of 3.5 months; of the six responders, four had undergone
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge